Kyverna Highlights 49% Median Walk-Time Improvement at One Year in Stiff Person Syndrome Trial
Market Chameleon (Thu, 24-Sep 7:54 AM)
Kyverna Therapeutics Secures Scalable Manufacturing for Miv-cel as BLA Submission Nears Completion
Market Chameleon (Mon, 27-Jul 11:46 AM)
